387 related articles for article (PubMed ID: 25441922)
1. Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: novel agents and approaches currently in clinical trials.
Sasine JP; Schiller GJ
Blood Rev; 2015 Jan; 29(1):1-9. PubMed ID: 25441922
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P; Vachhani P; Cortes JE
Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
[TBL] [Abstract][Full Text] [Related]
3. New and emerging therapies for acute myeloid leukaemia.
Davis JR; Benjamin DJ; Jonas BA
J Investig Med; 2018 Dec; 66(8):1088-1095. PubMed ID: 30127098
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Relapsed Acute Myeloid Leukemia.
Thol F; Ganser A
Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
[TBL] [Abstract][Full Text] [Related]
5. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
6. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
8. The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.
Short NJ; Ravandi F
Expert Rev Hematol; 2016 Jun; 9(6):529-34. PubMed ID: 27158854
[TBL] [Abstract][Full Text] [Related]
9. [Treatment and clinicopathological features of relapsed, refractory or elderly AML].
Ito Y
Rinsho Ketsueki; 2015 Oct; 56(10):1960-8. PubMed ID: 26458434
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
Tettamanti S; Magnani CF; Biondi A; Biagi E
Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
[TBL] [Abstract][Full Text] [Related]
11. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
[TBL] [Abstract][Full Text] [Related]
12. Update on antigen-specific immunotherapy of acute myeloid leukemia.
Buckley SA; Walter RB
Curr Hematol Malig Rep; 2015 Jun; 10(2):65-75. PubMed ID: 25896530
[TBL] [Abstract][Full Text] [Related]
13. Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly.
Kuendgen A; Germing U
Cancer Treat Rev; 2009 Apr; 35(2):97-120. PubMed ID: 18951721
[TBL] [Abstract][Full Text] [Related]
14. New agents for the treatment of acute myeloid leukemia.
Tallman MS
Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
[TBL] [Abstract][Full Text] [Related]
15. The past and future of CD33 as therapeutic target in acute myeloid leukemia.
Laszlo GS; Estey EH; Walter RB
Blood Rev; 2014 Jul; 28(4):143-53. PubMed ID: 24809231
[TBL] [Abstract][Full Text] [Related]
16. The thorny issue of relapsed acute myeloid leukemia.
Kubal T; Lancet JE
Curr Opin Hematol; 2013 Mar; 20(2):100-6. PubMed ID: 23385612
[TBL] [Abstract][Full Text] [Related]
17. Molecularly targeted therapy in acute myeloid leukemia.
Gill H; Leung AY; Kwong YL
Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
[TBL] [Abstract][Full Text] [Related]
18. Relapsed/refractory acute myeloid leukemia: any progress?
Schlenk RF; Müller-Tidow C; Benner A; Kieser M
Curr Opin Oncol; 2017 Nov; 29(6):467-473. PubMed ID: 28857842
[TBL] [Abstract][Full Text] [Related]
19. [Novel therapies for pediatric acute myeloid leukemia: building future strategies through incorporation of treatment currently used in adults].
Moritake H
Rinsho Ketsueki; 2020; 61(6):665-672. PubMed ID: 32624541
[TBL] [Abstract][Full Text] [Related]
20. Is there a standard of care for relapsed AML?
Medeiros BC
Best Pract Res Clin Haematol; 2018 Dec; 31(4):384-386. PubMed ID: 30466752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
